logo
First fossil hyena tracks found in South Africa – how expert animal trackers helped

First fossil hyena tracks found in South Africa – how expert animal trackers helped

Yahoo28-03-2025
'The art of tracking may well be the origin of science.' This is the departure point for a 2013 book by Louis Liebenberg, co-founder of an organisation devoted to environmental monitoring.
The connection between tracking in nature, as people have done since prehistory, and 'western' science is of special interest to us as ichnologists. (Ichnology is the study of tracks and traces.) We learned our skills relatively late in life. But imagine if we had learned as children and if, as adults, we tracked as if our lives depended on it? What additional visual and cognitive talents would we bring to our field work as scientists?
Our mission is to find and document the fossilised tracks and traces of creatures that existed during part of the Pleistocene Epoch, between 35,000 and 400,000 years ago, on the Cape coast of South Africa. Since 2008, through the Cape South Coast Ichnology project, based in the African Centre for Coastal Palaeoscience at Nelson Mandela University, more than 370 vertebrate tracksites have been identified. They have substantially complemented the traditional record of body fossils. Examples include trackways of giant tortoises and giraffe.
Given the challenges inherent in identifying such tracks, we wondered how hunters who've been tracking all their lives would view our work, and how age-old indigenous expertise might align with our approach.
Fortunately we could call on experts with these skills in southern Africa. The Ju/'hoansi (pronounced 'Juun-kwasi') San people of north-eastern Namibia are perhaps the last of southern Africa's indigenous inhabitants who retain the full suite of their ancient environmental skills. The Nyae Nyae conservancy in which they live gives them access to at least some of their historical land with its remaining wildlife. They still engage in subsistence hunting with bow and poisoned arrow and gather food that's growing wild.
A handful among them have been recognised as Indigenous Master Tracker, a title created by Liebenberg's CyberTracker initiative in recognition of their top-flight hunter-gatherer status. And so, late in 2023, the Master Trackers #oma ('Komma') Daqm and /uce ('Tchu-shey') Nǂamce arrived in Cape Town.
We were not the first to think along these lines. Ju/'hoansi Master Trackers have assisted scientists in the interpretation of hominin tracksites in French caves, and prehistoric tracks in the rock art record in Namibia. However, we knew that our often poorly preserved tracksites in aeolianites (cemented dunes) might present a stiffer challenge.
Our purpose was to compare our own interpretations of fossil trackways with those of the Master Trackers, and possibly find some we had overlooked. As we've set out in a recently published paper with the Ju/'hoansi trackers and our colleague Jan De Vynck as co-authors, they did exactly this, confirming the first fossil hyena trackway ever to be found.
The Late Pleistocene is not that far distant from the present (a mere 125,000 years), and many of the species that made tracks on the Cape south coast then are still with us. Some are extinct but have recognisable tracks, like the giant long-horned buffalo and giant Cape zebra.
We knew, though, that tracking in Kalahari sand, like the Ju/'hoansi do, is not the same as tracking on Pleistocene rock surfaces. Many of our tracks are preserved on the undersides of ceilings and overhangs, or are evident in profile in cliff exposures. Our track-bearing surfaces are usually small, and present no associated signs. We can't follow the spoor for any distance. We don't know at what time of day the tracks were made or the role of dew, and we have never succeeded in actually tracking down our quarry. Coprolites – fossilised droppings – are seldom found conveniently beside the tracks of the depositor.
We showed our new colleagues known fossil tracksites, without providing our own interpretations. #oma and /uce discussed these between themselves and presented their conclusions about what had made the tracks and how the animal had been behaving. We then shared our insights and our 3D photogrammetry data where applicable, and reached joint conclusions.
Soon they were identifying freshly exposed tracksites without our input, and were providing fascinating, new interpretations for sites which had puzzled us. For example, they saw ostrich tracks which we had missed, beside ostrich egg remnants, and concluded that we were probably looking at a fossilised ostrich nest. On another occasion they pointed out the distinctive track pattern of a scrub hare on the hanging wall of an eroded piece of cliff.
One of the most memorable experiences involved a 400,000-year-old trackway on a rock surface at Dana Bay, identified a few years earlier by local geologists Aleck and Ilona Birch. This rock had only been transiently exposed for a few days in the past decade, usually being covered by beach sand.
Our earlier interpretation had been that the trackmaker might have been a hyena, probably the brown hyena.
We were vindicated when our master tracker colleagues independently reached the identical conclusion. Examining our digital 3D images together fortified our collective judgement.
This was a big deal: it was the first fossil hyena trackway to be confidently identified, as previous examples had involved only individual tracks or poorly preserved possible trackway segments. Hyena trackways are distinctive: the forefoot tracks are substantially larger than those of the hindfoot.
Both of us are privileged to have university degrees and institutional affiliations. But there is another way in which acumen can be measured: the ability to use the ancient methods of discernment and pattern recognition to support and feed one's family and community through tracking, hunting and gathering.
What we have demonstrated, we believe, is a novel confluence of old and new ways to reveal fascinating features of the past. We use geological understanding, satellite technology, paleontological databases, tracking manuals and sophisticated dating methods. But hunter-gatherers see what escapes us and our drones: obscure strokes and enigmatic configurations on time-beaten surfaces. They tap an alternative knowledge base, both culturally received and cultivated from childhood.
The follow-through challenge must be to develop this partnership for mutual discovery and reward, understanding the past to better equip us for our uncertain future.
This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Charles Helm, Nelson Mandela University and Clive Thompson, Nelson Mandela University
Read more:
Tracking science: a way to include more people in producing knowledge
African communities have a lot of knowledge to share: researchers offer alternatives to Eurocentric ways of doing things
Traditional farming knowledge should be stored for future use: the technology to do this is available
Clive Thompson is a trustee of the Discovery Wilderness Trust, a non-profit organization that supports environmental conservation and the fostering of tracking skills.
Charles Helm does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

Yahoo

time25-07-2025

  • Yahoo

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active treatment arms compared to placebo, but did not meet statistical significance on the primary endpoint Inidascamine continues to exhibit a favorable safety and tolerability profile Full data set, including secondary endpoints and subgroup analyses will be forthcoming SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint. While the study did not achieve statistical significance on its primary endpoint of improvement on the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB) neurocognitive composite score at Week 6, inidascamine demonstrated a modest but consistent numerical improvement across the overall MCCB neurocognitive composite and multiple individual subdomains, including Symbol Coding, Speed of Processing and Verbal Learning (immediate recall). Directionally positive effects were also observed on the Virtual Reality Functional Capacity Assessment Tool (VRFCAT), a measure of real-world functional cognitive capacity. Inidascamine was well-tolerated, with a favorable safety profile consistent with previous studies. Importantly, no evidence of sedation, weight gain, or extrapyramidal symptoms was observed, which are side effects commonly associated with treatments used in people living with schizophrenia. Matt Pando, PhD, Chief Executive Officer and Co-Founder of Recognify Life Sciences, commented: 'Although we are disappointed that the study did not reach statistical significance on the primary efficacy endpoint, we are encouraged by the consistency of improvement signals across multiple cognitive and functional measures as well as replication on specific subsets of the cognitive measures; namely, symbol coding and verbal memory. These findings reinforce our commitment to addressing the significant unmet needs of cognitive impairment associated with numerous mental health and neurodegenerative conditions. Inidascamine continues to exhibit a strong safety profile, and we look forward to analyzing the full data set to better understand the outcome and inform potential next steps for the program.' The randomized, placebo-controlled, double-blind, Phase 2b clinical study enrolled 242 patients across the United States and Europe (NCT05686239). The trial evaluated the efficacy, safety, and tolerability of two doses of inidascamine versus placebo over a six-week treatment period. A comprehensive analysis of remaining secondary and exploratory endpoints, including subgroup analyses, is ongoing to determine whether there are identifiable responder populations or mechanistic insights that may guide future development. Keith Nuechterlein, PhD, Distinguished Professor in the UCLA Department of Psychiatry and Biobehavioral Sciences and co-chair of the MATRICS Neurocognition Committee, commented upon seeing these results: 'Developing treatments for cognitive impairment in schizophrenia is a complex challenge that requires persistence and innovation. I am encouraged by the inidascamine topline results showing consistent directional tendencies for improvement and look forward to seeing the full set of results.' Recognify plans to present additional results from the study at upcoming scientific meetings and will continue to evaluate strategic options for inidascamine based on the totality of data. Srinivas Rao, MD, PhD, Chief Executive Officer and Co-Founder of atai Life Sciences, added: 'CIAS remains a challenging therapeutic area with a significant unmet need. While we believe these results support the continued development of inidascamine by Recognify for CIAS as well as its potential application in other indications, as previously communicated, we intend to allocate atai's resources on our wholly owned pipeline of transformative psychedelic product candidates focused on affective disorders." About Inidascamine Inidascamine, formerly RL-007, is an orally available compound, with unique mechanisms of action for the treatment of cognitive impairment, that modulates cholinergic, glutamatergic and GABA-B receptors, thereby putatively altering the excitatory/inhibitory balance in the brain to produce pro-cognitive effects. It has previously been evaluated in ten clinical studies, including one in the CIAS indication, with over 600 unique participants dosed to date. Clinical studies of inidascamine suggest improvement in cognitive performance, particularly for verbal learning and memory and processing speed. About Schizophrenia and CIASSchizophrenia is a mental health disorder primarily characterized by hallucinations, delusions, and disordered thinking. This condition effects over 21 million people globally and approximately 2.4 million people in the United States, with around 300,000 new cases being diagnosed each year in the US. Cognitive deficits -present in approximately 80% of patients, is a core feature of the illness and contributes significantly to long-term disability and impairments in daily functioning. There are presently no effective pharmaceutical treatments approved for CIAS, representing a high unmet clinical need. About Recognify Life Sciences, Life Sciences is a clinical-stage biotech company on a mission to provide pro-cognitive treatments solutions to mental health and neurodegenerative disorders. The company is a strategic investment of atai Life Sciences. For more information about Recognify, please visit About atai Life Sciencesatai is a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes. atai's pipeline of psychedelic-based therapies includes BPL-003 (mebufotenin benzoate) for treatment-resistant depression (TRD), which is being advanced through a planned strategic combination with Beckley Psytech Limited; VLS-01 (buccal film DMT) also for TRD; and EMP-01 (oral R-MDMA) for social anxiety disorder. All three programs are in Phase 2 clinical development. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD. These programs aim to address the complex nature of mental health providing commercially scalable interventional psychiatry therapies that can integrate seamlessly into healthcare systems. For the latest updates and to learn more about atai's mission, visit or follow the Company on LinkedIn and on X. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). The words 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'initiate,' 'could,' 'would,' 'project,' 'plan,' 'potentially,' 'preliminary,' 'likely,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. All statements in this press release other than statements of historical fact are forward-looking statements, including, express or implied statements relating to, among other things: statements regarding Recognify Life Science's inidascamine (formerly RL-007) studies, data, or related strategic plans and objectives of management for future operations, capital expenditures and capital allocation. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond our control and which could cause actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by these forward-looking statements. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled 'Risk Factors' in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission ('SEC'), as such factors may be updated from time to time in atai's other filings with the SEC. atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law. Contact InformationInvestor Contact:IR@ atai Media Contact:PR@

Belite Bio to Participate in the BTIG Virtual Biotechnology Conference
Belite Bio to Participate in the BTIG Virtual Biotechnology Conference

Yahoo

time23-07-2025

  • Yahoo

Belite Bio to Participate in the BTIG Virtual Biotechnology Conference

SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will be participating in the BTIG Virtual Biotechnology Conference being held July 29-30, 2025. To schedule a one-on-one meeting with management, please reach out to your BTIG representative. About Belite BioBelite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite's lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at Media and Investor Relations Contact:Jennifer Wu ir@ Julie Fallonbelite@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Tirzepatide Tops TRT for Men With Hypogonadism and Obesity
Tirzepatide Tops TRT for Men With Hypogonadism and Obesity

Medscape

time23-07-2025

  • Medscape

Tirzepatide Tops TRT for Men With Hypogonadism and Obesity

San Francisco — Tirzepatide is a promising treatment for metabolic hypogonadism in men with obesity, new research suggested. In a study of 83 men with obesity, functional hypogonadism, and insulin resistance, those treated with the dual glucose-dependent insulinotropic peptide and glucagon-like peptide 1 (GLP-1) receptor agonist tirzepatide for 2 months had greater weight loss, increased endogenous testosterone production, and improved erectile dysfunction compared to those treated with transdermal testosterone replacement therapy (TRT) or who received no treatment. 'Tirzepatide offers a dual benefit, substantial weight loss and restoration of gonadal function in obese men. This may change first-line management strategies for metabolic hypogonadism, encouraging a shift away from immediate testosterone supplementation in select patients,' lead study author Rossella Cannarella, MD, research fellow in the Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy, told Medscape Medical News . She added, 'Unlike TRT, which suppresses gonadotropins, tirzepatide appears to restore axis function. This offers an alternative for functional hypogonadism that addresses root metabolic causes rather than symptomatically replacing testosterone.' Cannarella presented the findings at ENDO 2025: The Endocrine Society Annual Meeting. The data were also published recently in Reproductive Biology and Endocrinology . Asked to comment, session co-moderator Olena Klindukhova, MD, assistant professor at the Medical College of Wisconsin, Milwaukee, told Medscape Medical News , 'there are a number of good publications in the past on bariatric surgery patients who were able to achieve improvement in fertility, in testosterone level, and all aspects of sexual function. So, we were waiting the GLP-1 data to come in, and it's great to hear. It will definitely empower my clinical practice. Having patients achieve weight loss will improve their physiologic, natural production of testosterone. This gives us more validation.' Tirzepatide Tops Testosterone in Metabolic, Hormonal Improvements The study participants were allocated to three groups, based on their preferences, health status, and overall circumstances: 28 to tirzepatide (2.5 mg for the first month, increased to 5 mg in the second month), 30 to no pharmacological treatment, and 25 to transdermal testosterone. All were instructed to follow a low-calorie diet and to engage in 20 minutes per day of brisk walking. At baseline, all patients had ED, with International Index of Erectile Function (IIEF-5) scores ranging from 5 to 12. At least half in each group were classified as having severe ED. Baseline waist circumference was significantly higher in the no-treatment group, while baseline scores on the Binge Eating Scale (BES), percentage lean mass, and luteinizing hormone (LH) levels were all significantly higher in the tirzepatide-treated group. After 2 months, the tirzepatide group showed significantly greater improvements from baseline than the other two groups in body weight (-8.1%, vs -2.4% and -3.0% for lifestyle only and testosterone, respectively, P = .0007), BMI, waist circumference, fat mass, and BES score. The tirzepatide group also had a greater increase in lean mass than the lifestyle-alone group but not the testosterone group. All groups showed reductions in insulin resistance, with those in the two pharmacologic treatment groups showing greater reductions than the lifestyle-only group. The increase in IIEF-5 was higher in the tirzepatide group than the lifestyle-only group, and also higher than the testosterone group although not significantly. With tirzepatide, levels of LH, follicle-stimulating hormone (FSH), and total testosterone were significantly higher than in the other two groups, while 17β-estradiol (E 2 ) was lower (all P < .00001). The testosterone-treated group showed smaller changes in most parameters, including a slight increase in E 2 levels. Also asked to comment, session co-moderator Maja Stefanovic-Racic, MD, PhD, associate professor of medicine and director of the endocrinology, diabetes, and metabolism fellowship training program at the University of Pittsburgh School of Medicine, Pennsylvania, told Medscape Medical News , 'I was very impressed is that the GLP-1 improved erectile dysfunction, because we know that especially in obese men, adding testosterone often does not improve ED at all. This may relate to endothelial function outside of weight.' Indeed, Cannarella also pointed out that weight loss might not be the only mechanism contributing to all the observed improvements. 'While weight loss undoubtedly plays a major role, the magnitude and speed of hormonal recovery — along with increases in gonadotropins (LH, FSH) and SHBG [sex hormone-binding globulin] — suggest that tirzepatide may exert additional regulatory effects on the hypothalamic-pituitary-gonadal axis.' Klindukhova commented, 'from an endocrinologist standpoint, if there's a patient who is open to it, I would personally go for GLP-1 over testosterone.' Cannarella, Klindukhova, and Stefanovic-Racic had no disclosures.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store